ArticleFrontiers in allergy2025
Co-existence of chronic spontaneous urticaria with atopic dermatitis: clinical and immunological perspectives.
Article in Frontiers in allergy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Chronic Spontaneous Urticaria in the Era of Targeted Therapy: From Pathogenic Mechanisms to Precision Medicine.Pharmaceutics · 2026Review
- Chronic spontaneous cholinergic urticaria: advances in immunological mechanisms focusing on neuro-immune crosstalk and novel targeted therapeutic strategies.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic Spontaneous Urticaria (CSU) and Atopic Dermatitis (AD) are both immune-mediated inflammatory skin disorders that often co-exist with other atopic conditions such as asthma and allergic rhinitis. Their shared immunopathological pathways raise the question of a possible interrelationship. Objective: To evaluate the prevalence, clinical features, and immunological profiles of AD in patients with CSU and to explore implications for diagnosis and treatment. Methods: 425 CSU patients treated in Northern Israel between 2021 and 2024, were retrospectively analyzed. Disease activity was assessed using the Urticaria Activity Score-7 (UAS7) and Investigators' Global Assessment (IGA) for AD. The prevalence of asthma, total serum IgE levels, and therapeutic responses were evaluated. Results: Among the 425 CSU patients, 42 (10%) were also diagnosed with AD. Co-morbid patients had a higher frequency of asthma (40%) and high total IgE levels (67%) compared to CSU-only patients. A substantial subset of co-morbid cases required biologic treatments with Dupilumab, offering benefit in AD-dominant cases unresponsive to Omalizumab. Severe CSU was more prevalent in the CSU + AD group (though the prevalence was not statistically significant). Conclusion: CSU and AD frequently co-exist, likely due to overlapping T-cell-mediated immunopathogenic mechanisms. High total IgE and asthma comorbidity may indicate an underlying AD component in CSU patients. Recognition of this overlap is essential for appropriate therapeutic decision-making, including potential escalation to biologic agents targeting T-cell cytokine pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.